var data={"title":"Iopromide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iopromide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6391?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iopromide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iopromide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708950\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Not for intrathecal use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183947\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ultravist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14457201\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ultravist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183960\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Low Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183949\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Maximum recommended total dose of iodine is 86 g. Individualize dose taking into account patient's age, body weight, size of the vessel, and the rate of blood flow within the vessel. Consideration should also be made for the extent of opacification required, structure or area to be examined, disease processes, and equipment and technique used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aortography and visceral angiography:</b> Intra-arterial (370 mg iodine/mL): Volume and rate of administration based on blood flow and specific characteristics of vessels being studied; maximum dose for procedure: 225 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cerebral arteriography:</b> Intra-arterial (300 mg iodine/mL): Maximum dose for procedure: 150 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Carotid artery visualization: 3 to 12 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vertebral artery visualization: 4 to 12 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aortic arch injection: 20 to 50 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coronary arteriography and left ventriculography:</b> Intra-arterial (370 mg iodine/mL): Maximum dose for procedure: 225 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Left coronary: 3 to 14 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Right coronary: 3 to 14 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Left ventricle: 30 to 60 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral arteriography:</b> Intra-arterial (300 mg iodine/mL): Maximum dose for procedure: 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subclavian or femoral artery: 5 to 40 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aortic bifurcation for distal runoff: 25 to 50 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contrast-enhanced CT:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">300 mg iodine/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Head: 50 to 200 mL; maximum dose for procedure: 200 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bolus injection: 50 to 200 mL; maximum dose for procedure: 200 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rapid infusion: 100 to 200 mL; maximum dose for procedure: 200 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">370 mg iodine/mL:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Head: 41 to 162 mL; maximum dose for procedure: 162 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Body:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Bolus injection: 41 to 162 mL; maximum dose for procedure: 162 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rapid infusion: 81 to 162 mL; maximum dose for procedure: 162 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Excretory urography:</b> IV (300 mg iodine/mL): 1 mL/kg in patients with normal renal function; maximum dose for procedure: 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral venography:</b> IV (240 mg iodine/mL): Minimum amount to clearly visualize the structure under examination; maximum dose for procedure: 250 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183955\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac chambers and related arteries:</b> Children &gt;2 years and Adolescents: Intra-arterial (370 mg iodine/mL): 1 to 2 mL/kg; maximum dose for procedure: 4 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Contrast-enhanced CT or excretory urography:</b> Children &gt;2 years and Adolescents: IV (300 mg iodine/mL): 1 to 2 mL/kg; maximum dose for procedure: 3 mL/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062780\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962266\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use caution in renal impairment and in setting of combined renal and hepatic disease. Manufacturer recommends using lowest necessary dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962267\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183928\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ultravist: 31% (50 mL [DSC]); 50% (50 mL [DSC], 100 mL, 150 mL [DSC], 200 mL); 62% (50 mL, 75 mL [DSC], 100 mL, 125 mL [DSC], 150 mL [DSC], 200 mL, 500 mL); 77% (50 mL, 75 mL [DSC], 100 mL, 125 mL [DSC], 150 mL, 200 mL, 250 mL [DSC], 500 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183916\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183930\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For IV or intra-arterial use only. Solutions for injection should be as close to body temperature as possible. Hydrate patients prior to and following administration. Injection rates should be about equal to the flow rate in the vessel being injected. Allow sufficient time between each large injection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid infiltration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara 1983; Zenk 1981) or injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183929\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-arterial:</b> Enhance imaging in cerebral arteriography and peripheral arteriography, coronary arteriography and left ventriculography, visceral angiography and aortography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous:</b> Enhance imaging in peripheral venography, excretory urography, and contrast-enhanced computed tomographic imaging of the head and body (intrathoracic, intra-abdominal, and retroperitoneal regions) for the evaluation of neoplastic and nonneoplastic lesions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174550\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183920\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasodilatation (3%), chest pain (2%), bradycardia (&le;1%), complete atrioventricular block (&le;1%), coronary thrombosis (&le;1%), facial edema (&le;1%), flushing (&le;1%), hypertension (&le;1%), peripheral edema (&le;1%), peripheral vascular disease (&le;1%), syncope (&le;1%), vascular disease (&le;1%; vascular anomaly), ventricular premature contractions (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4%), agitation (&le;1%), anxiety (&le;1%), ataxia (&le;1%), chest discomfort (&le;1%), chills (&le;1%), confusion (&le;1%), dizziness (&le;1%), drowsiness (&le;1%), feeling hot (&le;1%), hypertonia (&le;1%), hypoesthesia (&le;1%), hypotension (&le;1%), malaise (&le;1%), myasthenia (&le;1%), neuropathy (&le;1%), paresthesia (&le;1%), seizure (&le;1%), speech disturbance (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (&le;1%), hyperhidrosis (&le;1%), pruritus (&le;1%), skin rash (&le;1%), urticaria (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase (&le;1%), polydipsia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (4%), vomiting (2%), dysgeusia (1%), abdominal distress (&le;1%), abdominal pain (&le;1%), constipation (&le;1%), diarrhea (&le;1%), dyspepsia (&le;1%), gastrointestinal pain (&le;1%), salivation (&le;1%), sore throat (&le;1%), stomach discomfort (&le;1%), tenesmus (&le;1%), upper abdominal pain (&le;1%), xerostomia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary urgency (2%), dysuria (&le;1%), urinary retention (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Increased hemoglobin (&le;1%), leukocytosis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (4%; edema, erythema, hematoma, hemorrhage, pain, skin rash, warm feeling)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (2%), arthralgia (&le;1%), limb pain (&le;1%), musculoskeletal pain (&le;1%), neck pain (&le;1%), tremor (&le;1%), weakness (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (1%), visual field defect (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (&le;1%), renal pain (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea (&le;1%), asthma (&le;1%), increased cough (&le;1%), dyspnea (&le;1%), hypoxia (&le;1%), pharyngeal edema (&le;1%), pharyngitis (&le;1%), pleural effusion (&le;1%), pulmonary hypertension (&le;1%), respiratory tract disease (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia, cerebrovascular accident, ischemic heart disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Cerebral edema (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Diabetes insipidus (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Mucous membrane disease (swelling; children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Fixed drug eruption (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Joint effusion (children), muscle cramps (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Aspiration, cyanosis, epistaxis (children), respiratory insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abnormal lacrimation, acute generalized exanthematous pustulosis, acute respiratory distress, amnesia, anaphylactic shock, anaphylactoid reaction, angina pectoris, angioedema, aphasia, atrial fibrillation, bronchospasm, cardiac failure, cerebral infarction, cerebral ischemia, coma, cortical blindness (transient), DRESS syndrome, dysphagia, enlargement of salivary glands, exacerbation of myasthenia gravis, hematuria, hypersensitivity reaction, hypotonia, laryngeal edema, laryngospasm, loss of consciousness, migraine (children), mydriasis, myocardial infarction, palpitations, paralysis, paresis, pulmonary edema, renal failure, shock, skin discoloration, Stevens-Johnson syndrome, tachycardia, tinnitus, toxic epidermal necrolysis, vasospasm, ventricular fibrillation, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183933\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal use; use in children with preparatory dehydration (eg, prolonged fasting and the administration of a laxative) before iopromide injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to iopromide or any component of the formulation; manifest hyperthyroidism; use in myelography, cerebral ventriculography, and cisternography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183918\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast media reactions: Serious and life-threatening reactions have occurred. Use extreme caution in patients with a history of previous reaction to contrast dye or iodine and patients with a known allergic disorder (eg, bronchial asthma, hay fever, food allergies) or other hypersensitivities. Monitor closely during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast-induced acute kidney injury: Acute kidney injury, including renal failure, may occur following intravascular administration of iodinated contrast media. Risk factors include patients with preexisting renal disease, advanced age, advanced vascular disease, heart failure, dehydration, diabetes mellitus, concomitant use of nephrotoxic agents or diuretics, multiple myeloma/paraproteinemia, or large doses or multiple doses of iodinated contrast media. Adequately hydrate patients prior to and following administration to minimize the risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatological effects: Severe cutaneous adverse reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to several weeks after administration; reaction severity may increase and time to onset may decrease with repeat administration. Avoid use in patients with a history of a severe cutaneous adverse reaction to iothalamate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. Extravasation may result in tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Serious thromboembolic events have been reported during angiographic procedures with both ionic and nonionic contrast agents. Clotting may occur when blood remains in contact with syringes containing iodinated contrast media. Therefore, meticulous intravascular administration technique is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or heart failure. Iodinated contrast media may result in an increased circulatory osmotic load and subsequent acute or delayed hemodynamic changes, especially following the use of large doses or repeated doses. Observe patients with cardiovascular disease for several hours after procedure for the development of delayed hemodynamic changes. Preparatory dehydration may contribute to acute renal failure in patients with heart failure or advanced vascular disease; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; these patients may have altered renal blood flow, increasing risk of nephrotoxicity. Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, especially those with concomitant renal impairment or when using both oral and IV contrast agents in close proximity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with thyroid disease; thyroid storm has been reported in patients with history of hyperthyroidism or with an autonomously functioning thyroid nodule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used (for intravascular administration) and monitor blood pressure closely throughout procedure. Therapy for treatment of hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in elderly patients and patients with diabetes, advanced vascular disease, and those who are dehydrated. Use lowest dose possible in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in patients with sickle cell disease; may promote sickling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For IV or intra-arterial use only. <b>[US Boxed Warning]: </b> <b>Not for intrathecal use</b>. <b>Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. </b>In contrast-enhanced computerized tomography, contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299532\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183922\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8880&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183925\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183935\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Iopromide crosses the placenta and was detected in a newborn gut and urine at birth (Vanhaesebrouck 2005). Thyroid dysfunction in the neonate has not been reported (ACR 2015; Kochi 2012). In general, use of iodinated contrast media should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2015; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20647502\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant's GI tract, breastfeeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015). The manufacturer recommends that caution be used if administered to a breastfeeding woman and that consideration be given to temporarily discontinuing breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183926\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function, blood pressure, hydration; monitor for extravasation during IV administration; monitor for hypersensitivity reactions for &ge;30 to 60 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coronary arteriography: ECG (coronary arteriography); vital signs; signs and symptoms of hypersensitivity; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183917\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Iopromide opacifies vessels in its path of flow, permitting radiographic visualization of internal structures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183932\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 16 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Main phase: 2 hours; Terminal phase: 6.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intravascular: Contrast enhancement: 15 to 120 seconds after bolus injection </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intravenous: Contrast enhancement: Kidneys: 5 to 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine 97% (as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323206\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ultravist Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50% (100 mL): $45.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62% (100 mL): $48.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">77% (150 mL): $84.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183936\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Clarograf (AR);</li>\n      <li>Prosure (KR);</li>\n      <li>Ultravist (AE, AT, AU, BE, BG, CH, CN, CR, CU, CY, CZ, DE, DK, DO, EC, EG, ES, ET, FI, FR, GR, GT, HN, HR, IE, IL, IN, IT, JO, LB, LK, LT, LU, LV, MT, NI, NL, NO, NZ, PA, PE, PL, PT, QA, RU, SA, SE, SG, SI, SK, SV, TR, TW, UA, VN, ZA, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Academy Position Statement:The Risk of Severe Allergic Reactions from the Use of Potassium Iodide for Radiation Emergencies,&rdquo; Adverse Reactions to Foods Committee and the Adverse Reactions to Drugs and Biologicals Committee. Available at http://www.aaaai.org/media/resources/academy_statements/position_statements/potassium_iodide.asp. Accessed October 24, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cutronea P, Polimeni G, Curcuruto R, et al, &ldquo;Adverse Reactions to Contrast Media: An Analysis From Spontaneous Reporting Data,&rdquo; <i>Pharmacol Res</i>, 2007, 56(1):35-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/17482832/pubmed\" target=\"_blank\" id=\"17482832\">17482832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. Available at <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kochi MH, Kaloudis EV, Ahmed W, Moore WH. Effect of in utero exposure of iodinated intravenous contrast on neonatal thyroid function. <i>J Comput Assist Tomogr</i>. 2012;36(2):165-169. doi: 10.1097/RCT.0b013e31824cc048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/22446353/pubmed\" target=\"_blank\" id=\"22446353\">22446353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy SW, Barrett BJ, and Parfrey PS, &ldquo;Contrast Nephropathy,&rdquo; <i>J Am Soc Nephrol</i>, 2000, 11(1):177-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/10616853/pubmed\" target=\"_blank\" id=\"10616853\">10616853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ultravist (iopromide) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ultravist (iopromide) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanhaesebrouck P, Verstraete AG, De Praeter C, Smets K, Zecic A, Craen M. Transplacental passage of a nonionic contrast agent. <i>Eur J Pediatr</i>. 2005;164(7):408-410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopromide-drug-information/abstract-text/15798909/pubmed\" target=\"_blank\" id=\"15798909\">15798909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8880 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708950\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183947\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14457201\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183960\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F183949\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F183955\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062780\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962266\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962267\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183928\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183916\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F183930\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183929\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174550\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F183920\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183933\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F183918\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299532\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F183922\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183925\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183935\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20647502\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F183926\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F183917\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F183932\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323206\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183936\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8880|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iopromide-patient-drug-information\" class=\"drug drug_patient\">Iopromide: Patient drug information</a></li></ul></div></div>","javascript":null}